DCF方案治疗晚期胃癌疗效观察

DCF Rregimen in Treatment of Advanced Gastric Cancer

目的 观察多烯紫杉醇联合顺铂、甲酰四氢叶酸／5-氟脲嘧啶治疗晚期胃癌的近期疗效和不良反应。方法 全组42例患者，均经病理检查确诊为腺癌，肝转移11例，肺转移7例，腹腔内淋巴结转移15例，腹膜转移6例，腹壁转移3例。应用多烯紫杉醇、顺铂、甲酰四氢叶酸／5-氟脲嘧啶（多烯紫杉醇75mg／m^2，静脉点滴2h，第1天；顺铂25mg／m^2，静脉点滴1h，第2—4天；甲酰四氢叶酸200mg／m^2，静脉点滴2h，第2—7天；5-氟脲嘧啶500mg／m^2，持续静脉点滴120h，第2～6天）方案治疗，21天重复。结果42例均可评价，总有效率为40．5％（17／42），其中完全缓解2例，部分缓解15例，稳定16例，进展9例，主要的不良反应为骨髓抑制和胃肠道反应。结论 DCF方案对晚期胃癌患者疗效好，不良反应可以耐受，值得临床推广应用。

Objective To study the efficacy and toxicities of ＇ Docetaxel ＋ CF/5-Fu ＋ DDP＇ combined chemotherapy in patients with advanced gastric cancer. Methods 42 patients with phathologically diagnosed advanced carcinoma were analysed. The metastatics were 11 of liver,7 of lung, 15 of abdominal cavity,s lymph node,6 of peritoneum,3 of abdominal wall. The regimen used was Docetaxel 75 mg/m^2 ,ivgtt 2 h,dl ;DDP 25 mg/m^2 ,ivgtt 1 h,d2,3,4;CF 200mg/m^2 ,ivgtt2h,d2 -7;5-Fu 500 mg/m^2 ,civ 120 h,d2 -6, every 3 weeks. Results All the 42 patients can be valued,and 2 （4.8%） achieved complete response, 15 （35. 7% ） achieved partial response, 16 （38. 1% ） stable disease, and 9 （21.4%） patients showed progressive disease. The median time to progression was 5.2 months [ 95% confidence interval （CI） 4.6 - 6.4 months ]. Median overall survival was 12.2 months. （95 % CI 4.8 - 17.2 months）. The most common side - effects were bone marrow restraint and gastrointestinal reactions. Conclusion ＇ Docetaxel ＋ CF/5-Fu ＋ DDP＇ combination chemotherapy is an effective and tolerable regimen in patients with advanced gastric cancer.